Planta Med 2010; 76(2): 137-139
DOI: 10.1055/s-0029-1186035
Pharmacology
Letters
© Georg Thieme Verlag KG Stuttgart · New York

Ganoderic Acids from Ganoderma lucidum: Inhibitory Activity of Osteoclastic Differentiation and Structural Criteria

Jie Liu1 , Jun Shiono1 , Kuniyoshi Shimizu1 , Ryuichiro Kondo1
  • 1Department of Forest and Forest Products Sciences, Faculty of Agriculture, Kyushu University, Fukuoka, Japan
Further Information

Publication History

received March 15, 2009 revised July 10, 2009

accepted July 14, 2009

Publication Date:
10 August 2009 (online)

Abstract

Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases. Ganoderma lucidum is known for medicinal effects such as anti-inflammatory and anti-bone resorption activities. In this study, we investigated the inhibitory effects of ganoderic acids isolated from G. lucidum on osteoclastic differentiation using RAW264 cells in vitro. A carbonyl in C7 is essential to elicit the inhibition of osteoclast differentiation.

References

  • 1 Manolagas S C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.  Endocr Rev. 2000;  21 115-137
  • 2 Suda T, Takahashi N, Martin T J. Modulation of osteoclast differentiation.  Endocr Rev. 1992;  13 66-80
  • 3 Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation.  Bone. 2007;  40 251-264
  • 4 Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds.  Planta Med. 2003;  3 193-201
  • 5 Hikino H, Mizuno T. Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies.  Planta Med. 1989;  4 385
  • 6 Miyamoto I, Liu J, Shimizu K, Sato M, Kukita A, Kukita T, Kondo R. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum.  Eur J Pharmacol. 2009;  602 1-7
  • 7 Yue Q X, Xie F B, Guan S H, Ma C, Yang M, Jiang B H, Liu X, Guo D A. Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes.  Cancer Sci. 2008;  99 1461-1470
  • 8 Komoda Y, Nakamura H, Ishihara S, Uchida M, Kohda H, Yamasaki K. Structures of new terpenoid constitutents of Ganoderma lucidum (FR.) KARST. (Polyporaceas).  Chem Pharm Bull. 1985;  33 4829-4835
  • 9 Arisawa M, Fujita A, Hayasi T, Shimizu M, Morita N, Kikuchi T, Kadota S, Tezuka Y. Revision of 1H- and 13C-NMR assignments of lanostanoids from Ganoderma lucidum by 2D-NMR studies.  J Nat Prod. 1988;  51 54-59
  • 10 Liu J, Kurashiki K, Shimizu K, Kondo R. Structure activity relationship for inhibition of 5α: reductase by triterpenoids isolated from Ganoderma lucidum.  Bioorg Med Chem. 2006;  14 8654-8660
  • 11 Watanabe T, Kukita T, Kukita A, Wada N, Toh K, Nagata K, Nomiyama H, Iijima T. Direct stimulation of osteoclastogenesis by MIP-1α: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL.  J Endocrinol. 2004;  180 193-201
  • 12 Liu J, Shiono J, Shimizu K, Yu H S, Zhang C Z, Jin F X, Kondo R. 20(R)-Ginsenoside Rh2, not 20(S), is a selective osteoclastogenesis inhibitor without any cytotoxicity.  Bioorg Med Chem Lett. 2009;  19 3320-3323

Prof. Ryuichiro Kondo

Department of Forest and Forest Products Sciences
Faculty of Agriculture
Kyushu University

6-10-1 Hakazaki, Higashiku

812–8581 Fukuoka

Japan

Phone: + 81 9 26 42 28 11

Fax: + 81 9 26 42 28 11

Email: ryukondo@agr.kyushu-u.ac.jp